Sarepta Therapeutics Inc to host SRP-9001 Micro-dystrophin R&D Day Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Colin Nigel Bristow - UBS Investment Bank, Research Division - Analyst : And thanks for the helpful presentation. Just a little bit more on the controlling for baseline characteristics and specifically trajectory. I think if you look at the (inaudible) data, certainly at the younger age, is like around 4, 4, 5. The different classes can have very similar baseline NSAA scores. And so how well does the time to rise control for this? And did you, at any point, consider just doing serial NSAA to just try and at least plot trajectory on a shorter-term basis? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.

Question: Yun Zhong - BTIG, LLC, Research Division - Analyst : So just a follow-up on the enrollment criteria. I wonder, are there any external natural history data besides what you have seen from the subgroup analysis from the Study 102 that suggest that in addition to making sure that the baseline condition is similar, you have to look at the 4 to 5 years old? That's a pretty narrow range to make sure -- I understand that increases data homogeneity, but just wondering if any additional evidence.

Question: Zhiqiang Shu - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst : I'm wondering if you can comment on how many patients in your Phase III EMBARK trial would be eligible for your 3 approved drugs, I guess if you think you are running into a situation where patients might receive those drugs in the trial and can potentially confound your results? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.